Table 2.
Treatment modalities and survival outcomes of patients with a diagnosis of mixed neuroendocrine non-neuroendocrine neoplasm in case reports according to disease stage.
| Localised (n = 48) | Advanced (n = 13) | ||
|---|---|---|---|
| Primary Tumour Site | Primary Tumour Site | ||
| Upper gastro-intestinal tract | 25 (52.1%) | Upper gastro-intestinal tract | 3 (23.1%) |
| Lower gastro-intestinal tract | 8 (16.7%) | Lower gastro-intestinal tract | 7 (53.8%) |
| Hepato-pancreato-biliary tract | 15 (31.2%) | Hepato-pancreato-biliary tract | 3 (23.1%) |
| Curative treatment | Palliative treatment (n = 31 *) | ||
| Surgery alone | 29 (60.4%) | Surgery alone | 2 (6.5%) |
| Surgery + CT | 16 (33.3%) | Surgery + CT | 6 (19.4%) |
| Surgery + CT + RT | 3 (6.3%) | CT + RT | 2 (6.5%) |
| CT alone | 9 (29.0%) | ||
| RT alone | 2 (6.5%) | ||
| Best supportive care | 4 (12.9%) | ||
| Unknown | 6 (19.4%) | ||
| Curative surgery | 48 (100%) | Palliative surgery | 8 (25.8%) |
| Perioperative CT or CT/RT | 19 (39.6%) | Palliative CT | 17 (54.8%) |
| CT regimen (+/−RT) | CT regimen (+/−Surgery +/−RT) | ||
| Platinum/Etoposide | 3 (15.8%) | Platinum/Etoposide | 6 (35.3%) |
| Platinum/Irinotecan | 1 (5.2%) | Platinum/Irinotecan | 1 (5.9%) |
| Fluoropyrimidine/Platinum/Irinotecan | 1 (5.2%) | Fluoropyrimidine/Platinum | 1 (5.9%) |
| Fluoropyrimidine/Platinum/Etoposide | 1 (5.2%) | Fluoropyrimidine/Oxaliplatin (+/−mAb) | 3 (17.6%) |
| Fluoropyrimidine/Oxaliplatin | 8 (42.1%) | Fluoropyrimidine/Irinotecan (+/−mAb) | 2 (11.8%) |
| Fluoropyrimidine alone | 2 (10.5%) | Fluoropyrimidine alone | 1 (5.9%) |
| Gemcitabine/Oxaliplatin | 2 (10.5%) | Gemcitabine | 1 (5.9%) |
| Regimen not specified | 1 (5.2%) | Regimen not specified | 2 (11.8%) |
| Non-NE-like regimens | 12 (66.7%) | Non-NE-like regimens | 8 (53.3%) |
| NEC-like regimens | 4 (22.2%) | NEC-like regimens | 7 (46.7%) |
| Both NEC-like and non-NE-like regimens | 2 (11.1%) | Both NEC-like and non-NE-like regimens | 0 |
| Median RFS (95%CI) (could be estimated for 48 patients) | 36 m (95%CI; 5.8–66.2) | Median PFS (95%CI) (could be estimated for 17 patients) | 5 m (95%CI; 3.6–6.4) |
| Median OS (95%CI) (could be estimated for 48 patients) | N.R. | Median OS (95%CI) (could be estimated for 20 patients) | 12m (95%CI; 4.4–19.6) |
n = number of patients; CT = chemotherapy; RT = radiotherapy; Platinum = cisplatin or carboplatin; mAb = monoclonal antibody; NEC-like regimens = regimens recommended for pure neuroendocrine carcinomas; non-NE-like regimens = regimens recommended for pure non-neuroendocrine malignancies (most commonly adenocarcinomas or squamous cell carcinomas) from the same site of origin; RFS = recurrence free survival; PFS = progression free survival; OS = overall survival; m = months; 95%CI = 95% confidence interval. * 13 patients with advanced disease at diagnosis plus 18 patients who relapsed after initial curative treatment.